Terns Pharmaceuticals Inc (TERN)

$6.78

-0.39

(-5.44%)

Market is closed - opens 8 PM, 14 Nov 2024

Performance

  • $6.68
    $7.52
    $6.78
    downward going graph

    1.47%

    Downside

    Day's Volatility :11.17%

    Upside

    9.84%

    downward going graph
  • $3.46
    $11.40
    $6.78
    downward going graph

    48.97%

    Downside

    52 Weeks Volatility :69.65%

    Upside

    40.53%

    downward going graph

Returns

PeriodTerns Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
6.7%
-2.6%
0.0%
6 Months
21.73%
2.6%
0.0%
1 Year
112.76%
15.9%
0.0%
3 Years
-15.55%
10.0%
-26.7%

Highlights

Market Capitalization
629.9M
Book Value
$3.11
Earnings Per Share (EPS)
-1.32
Wall Street Target Price
18.64
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-25.99%
Return On Equity TTM
-38.92%
Revenue TTM
1000.0K
Revenue Per Share TTM
0.04
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
1000.0K
EBITDA
-107.9M
Diluted Eps TTM
-1.32
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.27
EPS Estimate Next Year
-1.39
EPS Estimate Current Quarter
-0.34
EPS Estimate Next Quarter
-0.35

Analyst Recommendation

Buy
    78%Buy
    21%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Terns Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 174.93%

Current $6.78
Target $18.64

Technicals Summary

Sell

Neutral

Buy

Terns Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Terns Pharmaceuticals Inc
Terns Pharmaceuticals Inc
-5.91%
21.73%
112.76%
-15.55%
-61.01%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-19.05%
-15.96%
3.05%
26.75%
135.72%
Biontech Se
Biontech Se
-11.5%
14.67%
8.57%
-57.55%
473.15%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-5.07%
79.43%
62.99%
55.18%
196.92%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
1.07%
13.97%
29.31%
162.23%
136.6%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Terns Pharmaceuticals Inc
Terns Pharmaceuticals Inc
NA
NA
NA
-1.27
-0.39
-0.26
NA
3.11
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
20.49
20.49
1.23
44.94
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-3.18
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-1.88
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.35
0.42
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Terns Pharmaceuticals Inc
Terns Pharmaceuticals Inc
Buy
$629.9M
-61.01%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$91.0B
135.72%
20.49
33.61%
Biontech Se
Biontech Se
Buy
$26.1B
473.15%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$36.1B
196.92%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$133.1B
136.6%
32.84
-4.51%

Insights on Terns Pharmaceuticals Inc

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 57.4% return, outperforming this stock by 77.1%

Institutional Holdings

  • Orbimed Advisors, LLC

    9.02%
  • Vivo Capital, LLC

    7.32%
  • Deep Track Capital, LP

    7.22%
  • Soleus Capital Management, L.P.

    5.86%
  • BlackRock Inc

    4.88%
  • VR Adviser, LLC

    4.04%

Company Information

terns pharmaceuticals is a global biopharmaceutical company committed to discovering and developing molecularly-targeted, oral, small molecule drugs to treat liver diseases and cancers. the company combines expertise in disease biology and medicinal chemistry with a capital-efficient drug discovery model and extensive clinical development capabilities in china to advance its growing pipeline of drugs that are optimized against clinically-validated targets. based in san mateo, california and shanghai, terns is focused on bringing forward innovative therapeutic candidates with the potential to address significant unmet medical needs in china and globally.

Organization
Terns Pharmaceuticals Inc
Employees
66
CEO
Dr. Mark Joseph Vignola Ph.D.
Industry
Services

FAQs